Federico Bolognani is the vice president and head of Clinical Science at VectivBio in Basel, Switzerland.
VectivBio is a spinoff of Therachon with a focus on clinical-stage biotechnology to address conditions caused by well-understood molecular alterations that can be targeted with transformational therapeutics.
Bolognani received his M.D. and Ph.D. from the University Nacional de La Plata and was previously a faculty member at the University of New Mexico and at the Methodist Hospital.
Since 2009, Bolognani has focused his translational medicine efforts in an industrial setting, first at Novartis, later at F. Hoffmann-La Roche and most recently at Therachon, before his most recent move to VectivBio in 2019.